Stefano Tarantolo, MD
Hematology & Oncology · Omaha, NENPI 1205816667
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,781 of the $13,063 with a category attached, or 82.5%. 23 manufacturers reported payments, led by Sanofi at 40.6% of the total. Reporting peaked in 2022 at $5,408 and has fallen 89.9% since, to $548 in 2025.
Across 57 payments — averaging $229.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$5K
- Beigene USA, Inc.$3K
- Taiho Oncology, Inc.$2K
- Seagen Inc.$1K
- Johnson & Johnson$270
- AbbVie$193
- plus $1K from 17 others
Across 378 payments — averaging $9788.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.6M
- Beigene, Ltd.$524K
- Genentech, Inc.$407K
- Beone Medicines Ltd.$379K
- Takeda Pharmaceuticals U.S.A., Inc.$279K
- Janssen Research & Development, LLC$211K
- plus $271K from 15 others
What the payments were for
- Consulting fees$10,78183%
- Travel & lodging$3232%
- Food & beverage$1,94715%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 3 | $5,300 |
| Beigene USA, Inc. | 6 | $3,102 |
| Taiho Oncology, Inc. | 1 | $1,925 |
| Seagen Inc. | 1 | $1,100 |
| Johnson & Johnson | 3 | $270 |
| AbbVie | 5 | $193 |
| Advanced Accelerator Applications | 2 | $150 |
| Beone Medicines USA, Inc. | 1 | $149 |
| Genentech USA, Inc. | 2 | $142 |
| E.r. Squibb & Sons, L.L.C. | 8 | $122 |
| Blueprint Medicines Corporation | 1 | $122 |
| Myovant Sciences Inc. | 1 | $120 |
| Pfizer | 9 | $106 |
| Aimmune Therapeutics, Inc. | 1 | $44 |
| Servier Pharmaceuticals LLC | 2 | $39 |
| Recordati_rare_diseases_inc. | 1 | $39 |
| CTI Biopharma Corp. | 2 | $32 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $30 |
| Array Biopharma Inc | 2 | $21 |
| Novartis | 1 | $16 |
| EMD Serono, Inc. | 1 | $14 |
| Verity Pharmaceuticals Inc. | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,063 in reported general payments places this provider in the 75th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 124 | $2,626,353 |
| PomalystPomalidomide | 114 | $2,553,761 |
| BrukinsaZanubrutinib | 141 | $1,501,848 |
| Lenalidomide | 84 | $1,167,451 |
| ImbruvicaIbrutinib | 74 | $830,618 |
| JaypircaPirtobrutinib | 33 | $732,870 |
| VyndamaxTafamidis | 20 | $684,549 |
| JakafiRuxolitinib Phosphate | 26 | $563,117 |
| OjjaaraMomelotinib Dihydrochloride | 12 | $314,811 |
| SprycelDasatinib | 17 | $213,126 |
| EliquisApixaban | 99 | $74,018 |
| TasignaNilotinib Hcl | 13 | $65,470 |
| VenclextaVenetoclax | 16 | $64,716 |
| XareltoRivaroxaban | 48 | $49,736 |
| Acyclovir | 658 | $10,982 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $122 | $2,766,887131 claims |
| Beigene USA, Inc.Brukinsa | $3,102 | $1,501,848141 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $30 | $830,61874 claims |
| PfizerVyndamax, Eliquis | $106 | $758,567119 claims |
| NovartisTasigna | $16 | $65,47013 claims |
| AbbVieVenclexta | $193 | $64,71616 claims |
| Johnson & JohnsonXarelto | $270 | $49,73648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Omaha
- Mojtaba AkhtariOmaha$1.8M
- Luke NordquistOmaha$202K
- Apar Kishor GantiOmaha$138K
- Julie VoseOmaha$123K
- Peter SilbersteinOmaha$99K
- Krishna GundaboluOmaha$76K
- Vijaya BhattOmaha$58K
- Samer RennoOmaha$41K
- Timothy DoriusOmaha$24K
- Marcel DevettenOmaha$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.